Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKLR | P30613 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MME | P08473 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6558177 | 1.00 | PKLR (0.40) | PKLRCA2GAAMAPTCA4 | |
| SCHEMBL7575988 | 0.82 | NAALAD2 (0.47) | GAA | |
| SCHEMBL7575979 | 0.82 | NAALAD2 (0.47) | GAA | |
| SCHEMBL13760292 | 0.81 | KDM4E (0.41) | CA2GAAMAPTPPARGPPARA | |
| SCHEMBL5828020 | 0.81 | KDM4E (0.41) | CA2GAAMAPTPPARGPPARA | |
| SCHEMBL15583399 | 0.80 | CA2 (0.40) | PKLRCA2GAAMAPTCA4 | |
| SCHEMBL4456734 | 0.79 | PPARG (0.37) | GAAPPARGPPARALMNAHTT | |
| SCHEMBL4455175 | 0.79 | PPARG (0.37) | GAAPPARGPPARALMNAHTT | |
| SCHEMBL2501414 | 0.77 | PPARG (0.54) | PPARGPPARAMME | |
| SCHEMBL27719027 | 0.77 | PPARG (0.54) | PPARGPPARAMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0826671-B1 | HETEROCYCLIC AMIDE COMPOUNDS AND MEDICINAL USE OF THE SAME | MITSUBISHI PHARMA CORP (JP) | 2004-12-29 | — | — | EP | disclosed |
| CN-1504462-A | Pyrimidinyl derivatives as interleukin inhibitors | ������˹ҩƷ��˾ | 2004-06-16 | — | — | CN | disclosed |
| EP-0752987-B1 | PYRIMIDINYL DERIVATIVES AS INTERLEUKIN INHIBITORS | VERTEX PHARMA (US) | 2003-11-12 | — | — | EP | disclosed |
| EP-0752987-B1 | PYRIMIDINYL DERIVATIVES AS INTERLEUKIN INHIBITORS | VERTEX PHARMA (US) | 2003-11-12 | — | — | EP | disclosed |
| CN-1118458-C | Pyrimidinyl derivatives as interleukin inhibitors | FERTERX PHARMACEUTICAL INC (US) | 2003-08-20 | — | — | CN | disclosed |
| US-6407080-B2 | USED AS RESEARCH TOOLS IN PHARMACOLOGICAL, DIAGNOSTIC STUDIES AND TREATMENT OF DISEASES IN MAMMALS IN WHICH 1L-BETA-PROTEASE ACTIVITY IS IMPLICATED; ANTIINFLAMMATORY AGENT | VERTEX PHARMACEUTICALS INCORPORATED | 2002-06-18 | — | — | US | disclosed |
| US-6407080-B2 | USED AS RESEARCH TOOLS IN PHARMACOLOGICAL, DIAGNOSTIC STUDIES AND TREATMENT OF DISEASES IN MAMMALS IN WHICH 1L-BETA-PROTEASE ACTIVITY IS IMPLICATED; ANTIINFLAMMATORY AGENT | VERTEX PHARMACEUTICALS INCORPORATED | 2002-06-18 | — | — | US | disclosed |
| US-6407080-B2 | USED AS RESEARCH TOOLS IN PHARMACOLOGICAL, DIAGNOSTIC STUDIES AND TREATMENT OF DISEASES IN MAMMALS IN WHICH 1L-BETA-PROTEASE ACTIVITY IS IMPLICATED; ANTIINFLAMMATORY AGENT | VERTEX PHARMACEUTICALS INCORPORATED | 2002-06-18 | — | — | US | disclosed |
| US-20010003750-A1 | N-(pyrimidinyl)-aspartic acid analogs as interleukin-1beta converting enzyme inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2001-06-14 | — | — | US | disclosed |
| US-20010003750-A1 | N-(pyrimidinyl)-aspartic acid analogs as interleukin-1beta converting enzyme inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2001-06-14 | — | — | US | disclosed |
| US-5670494-A | N-(pyrimidinyl)-aspartic acid analogs as interleukin-1β converting enzyme inhibitors | SANOFT | 1997-09-23 | — | — | US | disclosed |
| US-5670494-A | N-(pyrimidinyl)-aspartic acid analogs as interleukin-1β converting enzyme inhibitors | SANOFT | 1997-09-23 | — | — | US | disclosed |
| US-5670494-A | N-(pyrimidinyl)-aspartic acid analogs as interleukin-1β converting enzyme inhibitors | SANOFT | 1997-09-23 | — | — | US | disclosed |
| CN-1149292-A | Pyrimidinyl derivatives as interleukin inhibitors | SANOFI WINTHROP INC (US) | 1997-05-07 | — | — | CN | disclosed |
| EP-0752987-A4 | PYRIMIDINYL DERIVATIVES AS INTERLEUKIN INHIBITORS | SANOFI WINTHROP INC (US) | 1997-04-09 | — | — | EP | disclosed |
| EP-0752987-A4 | PYRIMIDINYL DERIVATIVES AS INTERLEUKIN INHIBITORS | SANOFI WINTHROP INC (US) | 1997-04-09 | — | — | EP | disclosed |
| EP-0752987-A1 | PYRIMIDINYL DERIVATIVES AS INTERLEUKIN INHIBITORS | SANOFI WINTHROP, INC. (US) | 1997-01-15 | — | — | EP | disclosed |
| EP-0752987-A1 | PYRIMIDINYL DERIVATIVES AS INTERLEUKIN INHIBITORS | SANOFI WINTHROP, INC. (US) | 1997-01-15 | — | — | EP | disclosed |
| WO-1995026958-A1 | PYRIMIDINYL DERIVATIVES AS INTERLEUKIN INHIBITORS | SANOFI WINTHROP, INC. (US) | 1995-10-12 | — | — | WO | disclosed |
| WO-1995026958-A1 | PYRIMIDINYL DERIVATIVES AS INTERLEUKIN INHIBITORS | SANOFI WINTHROP, INC. (US) | 1995-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010003750-A1 | N-(pyrimidinyl)-aspartic acid analogs as interleukin-1beta converting enzyme inhibitors | IL1A, IL1B, IL1RN | PKLR 722/4885CA2 2746/4885GAA 338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.